TY - JOUR
T1 - Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor V(β) profiles
AU - Molldrem, Jeffrey J.
AU - Jiang, Yin Zheng
AU - Stetler-Stevenson, Maryalice
AU - Mavroudis, Dimitrios
AU - Hensel, Nancy
AU - Barrett, A. John
PY - 1998
Y1 - 1998
N2 - We have demonstrated that 44% of myelodysplastic syndrome (MDS) patients with cytopenia have a haematological response to antithymocyte globulin (ATG). Three ATG responders and two non-responders with refractory anaemia were further studied for lymphocyte-mediated inhibition of bone marrow using a standard CFU-GM assay. In responders, peripheral blood lymphocytes (PBL) added at a 5:1 ratio suppressed CFU-GM by 54 ± 9% (P = 0.04) and was reversed by ATG treatment. Pre-treatment marrow depleted of CD3 lymphocytes, increased CFU-GM by 32% (P = 0.02) in an ATG responder, but not in a non- responder. CD3 lymphocytes from 6-month post-treatment marrow did not inhibit pre-treatment CFU-GM, indicating ATG had affected the T cells. Pre-treatment marrow depleted of CD8 lymphocytes, increased CFU-GM by 60% (P = 0.01) and 49% (P = 0.03) in two ATG responders, but not in a non-responder. Inhibition required cell-cell interaction through MHC I. TCRVβ families, analysed by SSCP, changed from clonal to polyclonal in one ATG responder after 6 months, but clones persisted in a non-responder. These results indicate patients with refractory anaemia who respond to ATG have CD8 T-cell clones that mediate MHC-I-restricted suppression of CFU-GM which are replaced by polyclonal T cells that do not suppress CFU-GM after ATG treatment.
AB - We have demonstrated that 44% of myelodysplastic syndrome (MDS) patients with cytopenia have a haematological response to antithymocyte globulin (ATG). Three ATG responders and two non-responders with refractory anaemia were further studied for lymphocyte-mediated inhibition of bone marrow using a standard CFU-GM assay. In responders, peripheral blood lymphocytes (PBL) added at a 5:1 ratio suppressed CFU-GM by 54 ± 9% (P = 0.04) and was reversed by ATG treatment. Pre-treatment marrow depleted of CD3 lymphocytes, increased CFU-GM by 32% (P = 0.02) in an ATG responder, but not in a non- responder. CD3 lymphocytes from 6-month post-treatment marrow did not inhibit pre-treatment CFU-GM, indicating ATG had affected the T cells. Pre-treatment marrow depleted of CD8 lymphocytes, increased CFU-GM by 60% (P = 0.01) and 49% (P = 0.03) in two ATG responders, but not in a non-responder. Inhibition required cell-cell interaction through MHC I. TCRVβ families, analysed by SSCP, changed from clonal to polyclonal in one ATG responder after 6 months, but clones persisted in a non-responder. These results indicate patients with refractory anaemia who respond to ATG have CD8 T-cell clones that mediate MHC-I-restricted suppression of CFU-GM which are replaced by polyclonal T cells that do not suppress CFU-GM after ATG treatment.
KW - Bone marrow
KW - Immunosuppresion
KW - Myelodysplastic syndrome
KW - T lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=7344223859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7344223859&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2141.1998.00920.x
DO - 10.1046/j.1365-2141.1998.00920.x
M3 - Article
C2 - 9753062
AN - SCOPUS:7344223859
SN - 0007-1048
VL - 102
SP - 1314
EP - 1322
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 5
ER -